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Fatigue is a common symptom in many rheumatic diseases, including Rheumatoid Arthritis 1 
(RA). However, until recently healthcare professionals and researchers had not recognised 2 
its clinical significance and its impact o  patie ts’ li es. A turning point came in 2002, at the 3 
Patient Perspective Workshop of the Outcome Measure in Rheumatology (OMERACT) 4 
meeting, when patients highlighted the importance of fatigue.1 This led to the 5 
recommendation by OMERACT in 2006 that fatigue is included as a core outcome measure 6 
in clinical trials of RA treatments.2 The process by which the rheumatology community has 7 
come to recognise and focus on fatigue is an example of the value of patient involvement in 8 
setting research priorities. This awareness of fatigue as a patient priority has led many 9 
researchers over the last decade to work on better understanding the causes, assessment 10 
and management of fatigue.  11 
 12 
Qualitative research has provided insight into the nature of RA-related fatigue. Patients 13 
have described it as a complex and multidimensional symptom that can be overwhelming, 14 
unearned and unpredictable.3 It can include physical fatigue (e.g. levels of physical energy), 15 
cognitive fatigue (e.g. concentration and clarity of thought), living with fatigue (e.g. ability to 16 
carry out activities of daily living and social activities), and emotional fatigue (e.g. feelings of 17 
distress or upset).4 Quantitative research has established that it is highly prevalent, with 18 
levels similar to chronic fatigue syndrome.5 19 
 20 
In relation to impact, fatigue has been identified as the consequence of RA that best 21 
differentiates between levels of health-related quality of life.6 Patients have reported the 22 
negative effects of fatigue on their well-being, physical activities, emotions, mood, 23 
relationships, and social and family roles. From a societal perspective, fatigue is a significant 24 
predictor of high health care costs and the main reason for work disability and loss.7 The 25 
detrimental effects of fatigue are e a er ated  patie ts’ per eptio s that the s pto  is 26 
a challenge to manage and that it is not routinely addressed in clinical practice. This 27 
reluctance to discuss fatigue may reflect the lack of information and available treatments. 28 
Consequently, fatigue is widely recognised as important to patients, but how to manage and 29 
improve the symptom remains a major unmet need.  30 
 31 
A challenge in providing support for RA-related fatigue is that the causes are still unknown. 32 
Cross-sectional studies have found that fatigue is associated with pain severity and 33 
psychosocial factors including depression, but not disease activity.8  Overall, the current 34 
evidence suggests that fatigue is likely to be caused and maintained by the complex 35 
interaction of clinical factors (e.g. inflammation, pain, and disability), psychosocial issues 36 
(e.g. coping, mood, beliefs and behaviours) and personal factors (e.g. working, caring 37 
responsibilities and comorbidities) that may vary both between and within individuals over 38 
time.9 This is reflected in evidence from systematic reviews of non-pharmacological and 39 
pharmacological treatments for fatigue, which have identified the potential benefit of  40 
physical activity, psychosocial interventions and some biologic disease modifying anti-41 
rheumatic drugs (bDMARDs).10,11 The beneficial effect of bDMARDs suggests that 42 
inflammation has a significant pathobiological role although fatigue does not completely 43 
resolved. Experimental models found that systemic inflammation leads to increase in 44 
i tra ere ral i terfero  a d TNFα a ti it .12 Furthermore, in collagen-induced arthritis, an 45 
animal-model of RA, the blood brain barrier (BBB) is porous to cytokines.13 In patients with 46 
RA, a magnetic resonance spectroscopy study suggested that systemic inflammation may 1 
affect the neurochemical status of the CNS with high levels of choline to creatine ratio.14 2 
 3 
Possibly due to the lack of clarity around causal pathways, there is an increasing focus on 4 
the self-management of fatigue rather than the resolution or cure of the symptom. Recent 5 
evidence includes a multicentre randomised control trial using cognitive behavioural 6 
approaches. This study found that the impact of fatigue was reduced, with the positive 7 
effects maintained at two years.15 Self-management interventions are typically 8 
h pothesised to ork through the therapeuti  e ha is s of e ha i g patie ts’ self-9 
efficacy (the belief in their ability to achieve a desired outcome or goal). This is achieved by 10 
addressi g patie ts’ ill ess eliefs, their opi g strategies, a d their a epta e of fatigue as 11 
a symptom of their RA. In this study, the intervention included the use of daily activity 12 
diaries and goal setting to promote a shift in beliefs and progressive adaptations in how 13 
patients cope with fatigue, leading to better knowledge, confidence, and reactivation in 14 
everyday activities.  15 
 16 
Measurement is key to evaluating the usefulness of fatigue interventions, whether the focus 17 
is on reducing severity or managing the impact of the symptom. Although OMERACT 18 
included fatigue as a core outcome measure in RA, the lack of an RA specific validated 19 
outcome measure led to researchers adopting instruments developed for other conditions 20 
to assess fatigue. However, this was resolved in 2013 with the development, testing and 21 
publication of the Bristol Rheumatoid Arthritis Fatigue Scale.16 Designed in collaboration 22 
with patients, this multi-dimensional measure captures physical, cognitive, emotional and 23 
social aspects of fatigue. In addition, three numerical ratings scales enable researchers and 24 
healthcare professionals to measure fatigue severity, impact and coping. As the factors 25 
driving and maintaining RA-related fatigue are likely to vary between patients, insight into 26 
how individuals experience and perceive their fatigue could be an important step in 27 
providing tailored support.  28 
 29 
Patients have identified fatigue as a priority and a challenge to manage. In this supplement, 30 
authors have provided updates on the pathobiology, clinical assessment and management 31 
of fatigue. Clarifying our current understanding and identifying the gaps in our knowledge is 32 
an important step as we continue to look at ways of supporting patients with this common 33 
and difficult symptom.  34 
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